Thus, ChE inhibitors have been synthesized that selectively affect histamine H3 receptors (hH3R, regulates the release of acetylcholine, ACh) [22] and cannabinoid type 2 receptors (hCB2R, modulate the processes of the “silent” period of AD including neuroinflammation, oxidative stress and mitochondrial dysfunction) [23,24]. The gene discussed is HRH3; the disease is Alzheimer disease.